Ocugen closes $22.5M offering; net $20.85M extends cash runway into Q4 2026

Ocugen, Inc.

15M shares sold at $1.50/share in underwritten registered direct offering.
Net proceeds of $20.85M after commissions and expenses.
RTW Investments led the offering; Oppenheimer & Co. sole bookrunner.
Proceeds expected to fund operations into Q4 2026 (previously disclosed earlier runway).
Use of proceeds: general corporate, working capital, capital expenditures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.